North America Antibiotics Market Size

North America Antibiotics Market Size, Share & Analysis by 2026

North America Antibiotics Market By Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors), By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others), By Country, Industry Analysis and Forecast, 2020 - 2026

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Published Date : February-2021 | Number of Pages : 88 | Format : PDF

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Antibiotics Market, by Action Mechanism
1.4.2 North America Antibiotics Market, by Drug Class
1.4.3 North America Antibiotics Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals
3.2.4 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct – 2020, Jul) Leading Players

Chapter 4. North America Antibiotics Market by Action Mechanism
4.1 North America Cell Wall Synthesis Inhibitors Market by Country
4.2 North America Protein Synthesis Inhibitors Market by Country
4.3 North America DNA Synthesis Inhibitors Market by Country
4.4 North America RNA Synthesis Inhibitors Market by Country
4.5 North America Mycolic Acid Inhibitors Market by Country

Chapter 5. North America Antibiotics Market by Drug Class
5.1 North America Cephalosporin Market by Country
5.2 North America Penicillin Market by Country
5.3 North America Fluoroquinolone Market by Country
5.4 North America Macrolides Market by Country
5.5 North America Carbapenem Market by Country
5.6 North America Aminoglycosides Market by Country
5.7 North America Sulfonamides Market by Country
5.8 North America Others Market by Country

Chapter 6. North America Antibiotics Market by Country
6.1 US Antibiotics Market
6.1.1 US Antibiotics Market by Action Mechanism
6.1.2 US Antibiotics Market by Drug Class
6.2 Canada Antibiotics Market
6.2.1 Canada Antibiotics Market by Action Mechanism
6.2.2 Canada Antibiotics Market by Drug Class
6.3 Mexico Antibiotics Market
6.3.1 Mexico Antibiotics Market by Action Mechanism
6.3.2 Mexico Antibiotics Market by Drug Class
6.4 Rest of North America Antibiotics Market
6.4.1 Rest of North America Antibiotics Market by Action Mechanism
6.4.2 Rest of North America Antibiotics Market by Drug Class

Chapter 7. Company Profiles
7.1 GlaxoSmithKline PLC (GSK)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Johnson and Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Acquisition and Mergers:
7.3 Merck & Co., Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Product Launches and Product Expansions:
7.3.1.2 Approvals:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Recent strategies and developments:
7.4.4.1 Acquisition and Mergers:
7.4.4.2 Product Launches and Product Expansions:
7.5 Bayer AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Acquisition and Mergers:
7.7.5.2 Partnerships, Collaborations, and Agreements:
7.8 Abbott Laboratories
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.10. Eli Lilly and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities